Methamphetamine-associated heart failure: a systematic review of observational studies
- PMID: 36456204
- DOI: 10.1136/heartjnl-2022-321610
Methamphetamine-associated heart failure: a systematic review of observational studies
Abstract
Objective: To conduct a systematic review of observational studies on methamphetamine-associated heart failure (MethHF) .
Methods: Six databases were searched for original publications on the topic. Title/abstract and included full-text publications were reviewed in duplicate. Data extraction and critical appraisal for risk of bias were performed in duplicate.
Results: Twenty-one studies are included in the final analysis. Results could not be combined because of heterogeneity in study design, population, comparator, and outcome assessment. Overall risk of bias is moderate due to the presence of confounders, selection bias and poor matching; overall certainty in the evidence is very low. MethHF is increasing in prevalence, affects diverse racial/ethnic/sociodemographic groups with a male predominance; up to 44% have preserved left-ventricular ejection fraction. MethHF is associated with significant morbidity including worse heart failure symptoms compared with non-methamphetamine related heart failure. Female sex, methamphetamine abstinence and guideline-directed heart failure therapy are associated with improved outcomes. Chamber dimensions on echocardiography and fibrosis on biopsy predict the extent of recovery after abstinence.
Conclusions: The increasing prevalence of MethHF with associated morbidity underscores the urgent need for well designed prospective studies of people who use methamphetamine to accurately assess the epidemiology, clinical features, disease trajectory and outcomes of MethHF. Methamphetamine abstinence is an integral part of MethHF treatment; increased availability of effective non-pharmacological interventions for treatment of methamphetamine addiction is an essential first step. Availability of effective pharmacological treatment for methamphetamine addiction will further support MethHF treatment. Using harm reduction principles in an integrated addiction/HF treatment programme will bolster efforts to stem the increasing tide of MethHF.
Keywords: Cardiomyopathy, Dilated; Heart Failure, Diastolic; Heart Failure, Systolic; Systematic Reviews as Topic.
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Too much heterogeneity: envisioning a new approach to methamphetamine associated heart failure.Heart. 2023 Jan 11;109(3):162-163. doi: 10.1136/heartjnl-2022-321919. Heart. 2023. PMID: 36456205 No abstract available.
Similar articles
-
Methamphetamine-Associated Heart Failure Hospitalizations Across the United States: Geographic and Social Disparities.J Am Heart Assoc. 2021 Aug 17;10(16):e018370. doi: 10.1161/JAHA.120.018370. Epub 2021 Aug 7. J Am Heart Assoc. 2021. PMID: 34365802 Free PMC article.
-
Socioeconomic Burden of Rising Methamphetamine-Associated Heart Failure Hospitalizations in California From 2008 to 2018.Circ Cardiovasc Qual Outcomes. 2021 Jul;14(7):e007638. doi: 10.1161/CIRCOUTCOMES.120.007638. Epub 2021 Jul 13. Circ Cardiovasc Qual Outcomes. 2021. PMID: 34256572
-
Clinical and echocardiographic outcomes in heart failure associated with methamphetamine use and cessation.Heart. 2021 May;107(9):741-747. doi: 10.1136/heartjnl-2020-317635. Epub 2020 Oct 5. Heart. 2021. PMID: 33020227 Free PMC article.
-
A facilitated home-based cardiac rehabilitation intervention for people with heart failure and their caregivers: a research programme including the REACH-HF RCT.Southampton (UK): NIHR Journals Library; 2021 Feb. Southampton (UK): NIHR Journals Library; 2021 Feb. PMID: 33617178 Free Books & Documents. Review.
-
Methamphetamine-Associated Cardiomyopathy: Addressing the Clinical Challenges.Heart Lung Circ. 2022 May;31(5):616-622. doi: 10.1016/j.hlc.2021.12.015. Epub 2022 Feb 10. Heart Lung Circ. 2022. PMID: 35153149 Review.
Cited by
-
Community-Based Outreach for People Living With Methamphetamine-Associated Cardiomyopathy.JACC Case Rep. 2024 Oct 2;29(19):102598. doi: 10.1016/j.jaccas.2024.102598. eCollection 2024 Oct 2. JACC Case Rep. 2024. PMID: 39484319 Free PMC article.
-
Methamphetamine-induced cardiotoxicity: in search of protective transcriptional mechanisms.Herz. 2024 Dec;49(6):434-440. doi: 10.1007/s00059-024-05279-6. Epub 2024 Oct 25. Herz. 2024. PMID: 39455447 Free PMC article. Review.
-
Cardiomyopathy-Associated Hospital Admissions Among Methamphetamine Users: Geographical and Social Disparities.JACC Adv. 2024 Mar 13;3(7):100840. doi: 10.1016/j.jacadv.2024.100840. eCollection 2024 Jul. JACC Adv. 2024. PMID: 39130045 Free PMC article.
-
Facing a Tsunami: Methamphetamine Heart Failure Demands Novel Approaches.JACC Adv. 2024 Mar 13;3(7):100838. doi: 10.1016/j.jacadv.2024.100838. eCollection 2024 Jul. JACC Adv. 2024. PMID: 39130028 Free PMC article.
-
A review of methamphetamine use and stroke in the young.Front Neurol. 2024 Apr 24;15:1397677. doi: 10.3389/fneur.2024.1397677. eCollection 2024. Front Neurol. 2024. PMID: 38721123 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous